AzTrials
AzTrials

Participants With/Without Risk Factors for Metabolic DiseasesNUTRI-BRIDGENCT07110805

Nutrient And Non-Nutrient Intake, Relative Biomarkers and Their Health Effects In Apparently Healthy Participants

An observational study of Participants With/Without Risk Factors for Metabolic Diseases, run by University of Milan at 1 site in Italy.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This observational study aims to provide a comprehensive evaluation of dietary habits, physical activity, biomarkers involved in nutrition, metabolic and inflammatory status as well as intestinal permeability in apparently healthy volunteers aged over 18 years working or studying at the University of Milan. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
How many people
200 participants
Where
1 siteItaly
Study dates
1 Jun 2023to 1 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Both workers and students of the University of Milan aged over 18 years old volunteer to participate by responding to calls for study participation (e.g., a flyer or emails).

Who may be able to join

  • Apparently healthy volunteers
  • age ≥ 18 years old

Who cannot join

  • Pregnancy or breastfeeding
  • not willing to sign informed consent

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Division of Human Nutrition Department of Food, Environmental and Nutritional Sciences - DeFENS Università degli Studi di Milano

    Milan, 20133

Other trials in Italy

About this study

Official title: Nutrient And Non-Nutrient Intake, Relative Biomarkers And Their Health Impact In Different Target Populations - The NUTRIPOP-BRIDGE Study

This observational study aims to provide a comprehensive evaluation of dietary habits, physical activity, biomarkers involved in nutrition, metabolic and inflammatory status as well as intestinal permeability in apparently healthy volunteers aged over 18 years working or studying at the University of Milan. Furthermore, the analysis of the gut microbiota composition along with the omics approaches will be crucial for a better comprehension of the relationship between diet and health status in this population. As part of the OnFoods project (Project code PE00000003, Concession Decree No. 1550 of 11 October 2022 adopted by the Italian Ministry of University and Research, CUP D93C22000890001, Project title "ON Foods - Research and innovation network on food and nutrition Sustainability, Safety and Security - Working ON Foods"), the results will be valuable for suggesting targeted dietary and behavioral guidance in the context of public health policies.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dietary intake assessment

    Two repeated 24h recalls performed at least 3 weeks apart will be used to assess energy, nutrient and non-nutrient intake.

    Measured: At baseline and in 1 month

Secondary outcomes (22)
  1. Anthropometry

    Anthropometric measures including weight (in kilograms) and height (in meters) will be measured and combined to report body mass index (BMI) in kg/m^2.

    Measured: At baseline

  2. Assessment of fat free mass and fat mass

    Bio-Impendence Analysis (BIA) was used to assess fat free mass (FFM) in kg and fat mass (FM) in kg.

    Measured: At baseline

  3. Bioelectrical phase angle

    Bio-Impendence Analysis (BIA) was used to measure phase angle in degree.

    Measured: At baseline

  4. MediLite to assess adherence to Mediterranean Diet

    The questionnaire consists of 9 items assessing the daily consumption of fruit, vegetables, cereals, meat and meat products, dairy products, alcohol, and olive oil, and the weekly consumption of legumes and fish. Each item provides a score ranging from 0 to 2 points. The final score ranges from 0 (low adherence) to 18 (high adherence to the Mediterranean diet).

    Measured: At baseline

  5. MEDAS to assess adherence to Mediterranean Diet

    The questionnaire consists of 14 items evaluating the consumption of olive oil for cooking and dressing; daily intake of vegetables, fruits, butter and red meat; weekly intake of wine, legumes, fish, nuts, sweets, pastries or sugar-sweetened beverages; intake of white meat instead of red or processed red meat and the use of "sofrito" sauce. Each item provides a score ranging from 0 to 1 point. The final score ranges from 0 (low adherence) to 14 (high adherence to the Mediterranean diet).

    Measured: At baseline

  6. Assessment of physical activity level

    The short form of the International Physical Activity Questionnaire (IPAQ) consists of 7 items, exploring the intensity of physical activity based on metabolic equivalent of task (MET) consumption and sedentary behavior.

    Measured: At baseline

  7. Assessment of food consumption based on NOVA classification

    The NFFQ (NOVA food frequency questionnaire) consists of 94-item grouped in 9 sections headings: (1) fruit and nuts, (2) vegetables and legumes, (3) cereals and tubers, (4) meat and fish, (5) milk, dairy products, and eggs, (6) oils, fats, and seasonings, (7) sweets and sweeteners, (8) beverages and (9) other. Data are reported as g/day and total daily intake for each NOVA category.

    Measured: At baseline

  8. Markers of nutritional status

    Serum proteins involved in the assessment of nutritional status including albumin in mg/L and transferrin in mg/L as well as serum iron in mg/L will be evaluated through standardized analytical methods.

    Measured: At baseline

  9. Fasting glucose and lipid profile

    Markers involved in glucose and lipid metabolisms such as fasting glucose in mg/dl, total cholesterol in mg/dl, LDL-cholesterol in mg/dl, HDL-cholesterol in mg/dl and triglycerides in mg/dl will be evaluated in serum through standardized analytical methods.

    Measured: At baseline

  10. Liver function

    Markers involved in hepatic functions such as aspartate transaminase in U/L, alanine transaminase in U/L and gamma glutamyl transferase in U/L will be evaluated in serum through standardized analytical methods.

    Measured: At baseline

  11. Renal function

    Markers involved in renal functions including uric acid, azotemia and creatinine in mg/dl will be evaluated in serum through standardized analytical methods.

    Measured: At baseline

  12. Vitamins A, E and carotenoids

    Plasma vitamin A and vitamin E in µg/mL as well as bioactive compounds such as carotenoids in µg/mL will be evaluated through standardized analytical methods.

    Measured: At baseline

  13. Vitamin D

    Plasma vitamin D in ng/mL will be evaluated through standardized analytical methods.

    Measured: At baseline

  14. Vitamin B12 and folate

    Plasma vitamin B12 in ng/mL and folate in ng/mL will be evaluated through standardized analytical methods.

    Measured: At baseline

  15. C-reactive protein

    C-reactive protein in mg/L will be measured in serum through standardized analytical methods.

    Measured: At baseline

  16. Markers of systemic inflammation

    Markers involved in the inflammatory status such as TNF-α in pg/mL, IL-6 in pg/mL will be measured in serum through ELISA kits.

    Measured: At baseline

  17. Markers of intestinal permeability

    Intestinal permeability will be assessed by analyzing serum zonulin in ng/mL and ZO-1 in ng/mL using ELISA kits.

    Measured: At baseline

  18. Marker of intestinal permeability

    Serum calprotectin in µg/mL and fecal calprotectin in µg/g will be analyzed.

    Measured: At baseline

  19. Microbiota composition

    Microbiota composition in fecal samples will be evaluated through 16S rRNA sequencing methods.

    Measured: At baseline

  20. Proteomic analysis

    Proteomic will be performed on serum samples using Somascan.

    Measured: At baseline

  21. Metabolomic analysis

    Metabolomic will be performed on urine samples by mass spectrometry.

    Measured: At baseline

  22. Cellular DNA damage

    To assess damage at the cellular DNA level the Comet assay technique will be employed.

    Measured: At baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2025
  2. Study start1 Jun 2023
  3. Primary completion15 May 2025
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07110805
Sponsor's protocol ID
110/23
Acronym
NUTRI-BRIDGE
Status last verified
Jul 2025
First submitted
24 Jul 2025
Last updated
8 Aug 2025
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Participants With/Without Risk Factors for Metabolic Diseases, run by University of Milan at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dietary intake assessment (time frame: At baseline and in 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in